WuXi Biologics announced a USD$1.4 billion (S$2 billion) investment in Singapore in 2022. The CRDMO center will be the first-of-its-kind in Singapore, offering end-to-end biologics research, development and manufacturing solutions upon completion. It will add 120,000L of manufacturing capacity to…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has announced the successful outcome of the Phase 3 KEYNOTE-A18 trial, also recognized as ENGOT-cx11 This trial assessed KEYTRUDA, Merck’s anti-PD-1 therapy, combined with chemoradiotherapy (CRT) for…
Ionis has unveiled encouraging outcomes from its Phase 2 investigation of ION224, a DGAT2 antisense inhibitor aimed at addressing metabolic dysfunction-associated steatohepatitis (MASH), previously termed nonalcoholic steatohepatitis (NASH). The study, encompassing 160 patients over 51 weeks, successfully met its primary…
Blueprint Medicines Corporation (Nasdaq: BPMC) has announced that as of March 1, 2024, the Compensation Committee of its Board of Directors has approved the granting of non-qualified stock options to purchase a total of 2,615 shares of its common stock…
Novo Nordisk has announced today that the US Food and Drug Administration (FDA) has granted approval for an expanded label for Wegovy®. This approval, based on a supplemental New Drug Application (sNDA), extends the indication of Wegovy® to include the…
Eli Lilly and Company (NYSE: LLY) has announced that the U.S. Food and Drug Administration (FDA) plans to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) to discuss the Phase 3 TRAILBLAZER-ALZ 2 trial,…
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on seralutinib for pulmonary arterial hypertension (PAH) treatment, reported its financials for Q4 and full-year 2023 and updated on business progress. Faheem Hasnain, Chairman, Co-Founder, and CEO, stated, “We initiated…
Vivani Medical, Inc. (Nasdaq: VANI), a pioneering biopharmaceutical company in the preclinical stage, has recently announced a significant move towards advancing its innovative long-term drug implants. In a registered direct offering, the company has entered into a securities purchase agreement…
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that Shionogi and Osaka University (Location: Suita, Osaka, President: Shojiro Nishio) have established a joint research laboratory (research lab’s name: Joint Research Laboratory…
AbbVie (NYSE: ABBV) announces today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the supplemental Biologics License Application (sBLA) concerning epcoritamab-bysp, a subcutaneously administered T-cell engaging bispecific antibody. This treatment targets adult patients with relapsed…
Bristol Myers Squibb (NYSE: BMY) has confirmed the conclusion of its tender offer, initially announced, to acquire all outstanding shares of RayzeBio, Inc. (Nasdaq: RYZB) common stock at a price of $62.50 per share in cash, totaling approximately $4.1 billion.…
The U.S. Food and Drug Administration (FDA) has given priority review status to the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab), marking its sixth potential indication. This review targets its use as an add-on maintenance treatment for specific adult…
